PhRMA’s new principles on conducting clinical trials take effect

By Zachary Brennan contact

- Last updated on GMT

Related tags: Clinical trial, Pharmacology, Investigational new drug

PhRMA’s new principles on conducting clinical trials take effect
Last week, a new chapter of PhRMA’s Principles on the Conduct of Clinical Trials and Communication of Clinical Trial Results went into effect, detailing efforts to raise awareness around expanded access programs, which provide investigational drugs for certain patients who are ineligible or unable to participate in a clinical trial.  

Under the chapter, industry group PhRMA (Pharmaceutical Researchers and Manufacturers of America) notes that physicians can apply for expanded access to an unapproved drug for their patients to treat a serious or life-threatening disease or condition when there are no other comparable or satisfactory alternative treatment options and when patients are ineligible or unable to participate in a clinical trial.

It is important for the patient’s physician and the medical staff at a biopharmaceutical company to discuss whether it provides the best possible treatment option for the patient before going through the FDA process​,” PhRMA says.

The industry group lays out a number of considerations for biopharma companies to follow when providing patients with access to an unapproved investigational drug outside of a clinical trial. The considerations include that the illness must be serious or life-threatening, the investigational drugs should be active in clinical development, and “there should be sufficiently robust preliminary safety and efficacy data, including dosing information, to determine that the preliminary benefit-risk balance is positive for the specific indication for which the request is made​.”

In addition, granting access to an investigational drug through an expanded access program should not delay, interfere or compromise the completion of clinical trials that are intended to support the drug’s approval, according to PhRMA.

As far as eligibility for patients seeking expanded access to an investigational drug outside of a clinical trial, PhRMA notes that “geographic limitations alone would generally not be considered a barrier to participation in clinical trials​.”

PhRMA also calls on biopharma companies to establish telephone or internet-based information sources to facilitate communication about expanded access programs.

In addition to the information on expanded access programs, the PhRMA chapter also outlines ways for companies to protect research participants, properly conduct clinical trials, ensure objectivity in research, and ways to provide more information about clinical trials.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us

Products

View more

Webinars